Data Sheet 1_COVID-19 vaccination and clinical outcomes of immune checkpoint inhibitors th

Hongyan Xi's meta-analysis document, uploaded to figshare on 2026-04-16, synthesizes results from 10 observational studies comprising 4,929 cancer patients. The 955.5 KB DOCX file reports pooled hazard ratios and odds ratios for survival and response outcomes. It concludes COVID-19 vaccination is associated with improved progression-free and overall survival in patients receiving immune checkpoint inhibitors.

Use Cases

• Assessing the association between COVID-19 vaccination and progression-free survival based on pooled hazard ratios.
• Evaluating the impact of vaccination on overall survival in ICI-treated patients.
• Comparing objective response rates between vaccinated and unvaccinated cohorts.
• Analyzing subgroup results by vaccine platform or cancer type mentioned in the description.

Strengths

• Analysis is based on 10 studies comprising 4,929 patients, providing a substantial sample size.
• Results include specific pooled effect sizes (e.g., HR=0.66 for PFS, HR=0.51 for OS) with 95% confidence intervals.
• The document is licensed under CC-BY-4.0, allowing for reuse and redistribution.

Limitations

• The dataset is a 955.5 KB DOCX document, which is a small text file and not a structured data table.
• Row count and column-level documentation are absent; data must be extracted manually from the report.
• The observational nature of the underlying studies, as noted in the conclusions, limits causal inference.

Provenance

Source

Hongyan Xi via figshare.

Collection Method

Systematic review and meta-analysis of observational studies from PubMed, Embase, and Scopus.

Time Range

Studies searched from 2020 to December 31, 2025.

Freshness

Last updated 2026-04-16 05:24:07.

Geography

null